EQRx, Inc., a pharmaceutical company, engages in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases in the United States. The company's pre-registrational programs in Phase III clinical trial include Aumolertinib, an epidermal growth factor receptor (EGFR) inhibitor for the treatment of patients with EGFR-mutated non-small cell lung cancer (NSCLC); and Sugemalimab, an anti-programmed death-ligand 1 antibody for the treatment of Stage III and Stage IV NSCLC. Its other programs in pipeline include clinical and pre-clinical stage assets, which comprise Lerociclib, a small molecule cyclin-dependent kinase 4/6 inhibitor, which is in Phase II clinical trials in patients with metastatic breast cancer; EQ176, an anti-programmed death-1 antibody that is in Phase III trials for the treatment of patients with primary liver cancer; and EQ121, a selective janus kinase-1 inhibitor that is in various Phase I trials. The company was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.
IPO Year: 2021
Exchange: NASDAQ
Website: https://www.eqrx.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
11/14/2022 | Neutral → Underweight | JP Morgan | |
11/11/2022 | $8.00 → $5.00 | Buy → Neutral | Goldman |
11/11/2022 | $5.60 → $3.20 | Buy → Hold | Jefferies |
8/16/2022 | $5.50 | Neutral | JP Morgan |
6/13/2022 | $8.00 | Buy | Goldman |
4/22/2022 | Outperform | Cowen | |
3/18/2022 | $5.60 | Buy | Jefferies |
4 - EQRx, Inc. (0001843762) (Issuer)
4 - EQRx, Inc. (0001843762) (Issuer)
4 - EQRx, Inc. (0001843762) (Issuer)
4 - EQRx, Inc. (0001843762) (Issuer)
4 - EQRx, Inc. (0001843762) (Issuer)
4 - EQRx, Inc. (0001843762) (Issuer)
4 - EQRx, Inc. (0001843762) (Issuer)
4 - EQRx, Inc. (0001843762) (Issuer)
4 - EQRx, Inc. (0001843762) (Issuer)
4 - EQRx, Inc. (0001843762) (Issuer)